Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status

Pathology ◽  
2020 ◽  
Author(s):  
Eltjona Rrapaj ◽  
Lorenzo Giacometti ◽  
Paolo Spina ◽  
Michela Salvo ◽  
Guido Alessandro Baselli ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Pleural Mesothelioma ◽  
Poor Prognosis ◽  
Performance Status ◽  
Pleural Mesothelioma ◽  
Good Performance Status ◽  
Programmed Cell Death 1

scholarly journals Analysis of Expression of Programmed Cell Death 1 Ligand 1 (Pd-L1) in Malignant Pleural Mesothelioma (Mpm)

2014 ◽  
Vol 25 ◽  
pp. v1 ◽  
Author(s):  
S. Cedres ◽  
S. Ponce Aix ◽  
J. Zugazagoitia ◽  
A.B. Anguita ◽  
I. Sansano ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Programmed Cell Death 1

scholarly journals Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0121071 ◽  
Author(s):  
Susana Cedrés ◽  
Santiago Ponce-Aix ◽  
Jon Zugazagoitia ◽  
Irene Sansano ◽  
Ana Enguita ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Programmed Cell Death 1

Analysis of expression of PTEN/PI3K pathway and programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e18540-e18540
Author(s):  
Susana Cedres Perez ◽  
Santiago Ponce Aix ◽  
Irene Sansano ◽  
Alejandro Navarro ◽  
Alex Martinez Marti ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Pleural Mesothelioma ◽  
Pi3k Pathway ◽  
Pleural Mesothelioma ◽  
Programmed Cell Death 1

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Lung Cancer ◽  
2016 ◽  
Vol 96 ◽  
pp. 1-6 ◽  
Author(s):  
S. Cedrés ◽  
S. Ponce-Aix ◽  
N. Pardo-Aranda ◽  
A. Navarro-Mendivil ◽  
A. Martinez-Marti ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Pleural Mesothelioma ◽  
Pi3k Pathway ◽  
Pleural Mesothelioma

scholarly journals Nivolumab In Combination With Ipilimumab (Opdivo-Yervoy)

2021 ◽  
Vol 1 (8) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Systemic Treatment ◽  
Performance Status ◽  
Pleural Mesothelioma ◽  
Good Performance Status ◽  
The Cost ◽  
Public Drug

CADTH recommends that Opdivo in combination with Yervoy (nivolumab plus ipilimumab) should be reimbursed by public drug plans for the treatment of malignant pleural mesothelioma (MPM) if certain conditions are met. Opdivo plus Yervoy should only be reimbursed if prescribed by clinicians with experience in immuno-oncology and treating MPM and if the cost of Opdivo plus Yervoy is reduced. Opdivo plus Yervoy should only be covered to treat patients who have not received prior systemic treatment for MPM and who have good performance status at the start of treatment.

Prognostic Role of Programmed Cell Death 1 Ligand 1 (PD-L1) in Resectable Pleural Mesothelioma

2020 ◽  
Author(s):  
Hyun-Sung Lee ◽  
Masatsugu Hamaji ◽  
Nihanth Palivela ◽  
Hee-Jin Jang ◽  
Taylor Splawn ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Pleural Mesothelioma ◽  
Prognostic Role ◽  
Programmed Cell Death 1

scholarly journals MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma

Oncotarget ◽  
2018 ◽  
Vol 9 (25) ◽  
pp. 17300-17308 ◽  
Author(s):  
Lorenzo Nicolè ◽  
Rocco Cappellesso ◽  
Tiziana Sanavia ◽  
Vincenza Guzzardo ◽  
Ambrogio Fassina
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Down Regulation ◽  
Over Expression ◽  
Programmed Cell Death 4
Sign in / Sign up

Export Citation Format

Share Document